Elena García Armada
Most deep technology never leaves the laboratory. The gap between a working prototype and a regulated, commercially viable product is where ambitious R&D programmes quietly fail, and where boards lose patience with science-led ventures. The harder question for leadership is what discipline lets a research breakthrough survive the journey to market without losing its scientific integrity.
Elena García Armada is the roboticist behind the world’s first paediatric exoskeleton, and the founder who turned a CSIC research project into Marsi Bionics, a commercial medical-device company.
Full Profile
Why organisations work with Elena García Armada
- She has done what most deep-tech founders only describe: taken a robotics breakthrough from CSIC laboratory bench into certified clinical use, through a company she still runs.
- Her European Inventor Award Popular Prize from the European Patent Office gives her a credential most innovation speakers cannot match, anchored in a specific patented invention, not a body of opinion.
- She speaks fluently across two worlds that rarely meet on the same stage: tenured senior scientist at CSIC and CEO of a regulated medical device company, with operational responsibility for staff, capital, and clinical outcomes.
- Her work sits at the intersection of robotics, AI-driven control, and biomedical engineering, which makes her credible on the practical question of how emerging technologies translate into products under real regulatory and commercial constraints.
Biography highlights
- CEO and co-founder of Marsi Bionics, the CSIC-UPM spin-off that brought paediatric exoskeletons to clinical use.
- Senior tenured scientist at the Centre for Automation and Robotics (CAR), CSIC-UPM, leading research on legged robots and exoskeletons.
- PhD in robotic engineering, Polytechnic University of Madrid; postdoctoral training at MIT’s Leg Laboratory.
- European Inventor Award Popular Prize 2022, European Patent Office; finalist EU Women Innovators Award 2021; Gold Medal of the Spanish Red Cross 2022.
- Author of “Los robots y sus capacidades” and “Robots” (Catarata / Editorial CSIC).
- Doctor honoris causa, Miguel de Cervantes European University, 2023; Premio Nacional Reina Letizia for Research and Innovation, 2023.
Biography
Most exoskeletons in research labs do not fit children. The mechanics, the weight, the control systems, and the regulatory pathway for a paediatric medical device are harder than the adult equivalents, and the commercial incentives to solve them are weaker. ATLAS 2030, the world’s first adaptable paediatric exoskeleton, exists because Elena García Armada chose to work on the harder version of the problem.
The technical work began at the Centre for Automation and Robotics, the joint CSIC and Polytechnic University of Madrid centre where she is a senior tenured scientist. The commercial work began in 2013, when she co-founded Marsi Bionics as a CSIC spin-off to take the technology out of the lab and into rehabilitation centres and hospitals.
Her credentials sit on both sides of that journey. Postdoctoral training at MIT’s Leg Laboratory on the research side; CEO of a regulated medical device company on the commercial side. The European Patent Office awarded her the Popular Prize of the 2022 European Inventor Award for the underlying invention, and the Spanish state has recognised the social impact with the Premio Nacional Reina Letizia and the Red Cross Gold Medal.
What is unusual is not the recognition. It is that the same person holds the patent, runs the company, and answers for the clinical outcomes. That combination is rare in deep-tech innovation, and it is what makes her useful to boards thinking about how science-led ventures actually become businesses.
Key speaking topics
- Deep-tech commercialisation
- Robotics and exoskeleton technology
- Biomedical engineering and assistive devices
- Innovation in regulated industries
- Science-led entrepreneurship
- AI-driven control systems in robotics
- Women in STEM and inclusive innovation
Ideal for
- Boards and executive teams investing in or running deep-tech and medtech ventures
- Innovation, R&D and CTO functions seeking credible perspective on lab-to-market translation
- Healthcare and life-sciences leaders working on assistive and rehabilitation technology
- Audiences focused on STEM talent strategy and women in engineering
Audience outcomes
- A concrete view of what it takes to move a robotics breakthrough from research into a regulated, commercial product
- A sharper sense of how academic science, patents, and venture-building reinforce one another when handled by the same hand
- Direct exposure to a working case of paediatric exoskeleton design, with the engineering, clinical, and commercial choices made visible
- A grounded perspective on the role of women in technical leadership of European deep-tech
Talks
A first-person account of how the paediatric exoskeleton went from a research idea inside CSIC to a clinically deployed device.
Key takeaways:
- How a deep-tech idea is structured to survive both peer review and regulatory approval
- The specific engineering and clinical decisions behind ATLAS 2030
- What founders running science-led companies need from boards and investors
A talk on the route into engineering and the practical case for broader participation in robotics and biomedical research.
Key takeaways:
- The realities of a research and entrepreneurial career in robotics
- Where women remain under-represented in European deep-tech and why it matters commercially
- How organisations can support technical talent earlier in the pipeline